Business context and reporting period
Ekso Bionics Holdings, Inc. filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2015. The company develops and sells wearable exoskeletons for medical and other applications, and provides engineering and research services. The request metadata names Chronoscale Holdings Corp., but the filing identifies Ekso Bionics Holdings, Inc. as the registrant.
Key financial metrics
Amounts below are in millions of dollars, except per-share data and percentages.
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $2.114 | $1.197 | $3.803 | $2.259 |
| Gross profit | $0.502 | $0.045 | $0.905 | $0.525 |
| Gross margin | 23.7% | 3.8% | 23.8% | 23.2% |
| Operating expenses | $6.137 | $4.357 | $10.633 | $8.728 |
| Operating loss | $(5.635) | $(4.312) | $(9.728) | $(8.203) |
| Net income (loss) | $(5.645) | $56.128 | $(9.760) | $(25.638) |
| Basic loss per share | $(0.06) | $0.72 | $(0.10) | $(0.35) |
| Operating cash use | Not separately provided | Not separately provided | $8.462 | $8.605 |
Q2 revenue comprised medical devices of $1.048 million and engineering services of $1.066 million. For the six months, the respective amounts were $2.033 million and $1.770 million. Cash was $16.251 million at June 30, 2015, down from $25.190 million at year-end 2014. Current assets were $22.182 million and current liabilities $8.357 million. Total liabilities were $12.971 million; notes payable and capital lease obligations totaled about $96,000. Accumulated deficit was $81.561 million.
Changes versus comparable periods
- Q2 revenue rose 77% year over year; six-month revenue rose 68%. Management attributed growth to more medical-device sales recognized and increased Ekso Labs projects.
- Q2 gross profit improved by $457,000 and gross margin increased about 20 percentage points. Medical-device service costs rose as the company upgraded its installed fleet; management expected elevated costs to continue for another quarter or two. Engineering-services margins improved and more than offset medical-device margin pressure.
- Operating expenses increased 41% in Q2 and 22% for the first half. Higher sales and marketing and research and development spending drove the increases, including investment in industrial product development.
- The Q2 2014 net income included a $60.458 million non-cash warrant-liability gain; the first half of 2014 included a $16.979 million warrant-liability loss. These unusual items make reported net results poorly comparable. The warrants were amended in November 2014 and are no longer carried as liabilities.
- Cash declined by $8.939 million during the first half of 2015. Operating and investing activities used $8.462 million and $559,000, respectively; financing provided $82,000.
Outlook, risks and unusual items
- Management estimated that, based on average monthly cash use of approximately $1.5 million and stated assumptions, existing resources would meet obligations into the second quarter of 2016. It said additional financing would be needed and intended to pursue collaborations, equity, debt or warrant solicitations within the next two to four quarters. Financing availability was not assured; equity issuance could dilute shareholders, and failure to raise funds could require spending cuts or curtailed operations.
- The FDA had classified powered exoskeletons as Class II, requiring 510(k) clearance. Ekso’s submission, filed December 24, 2014, remained under review. The company continued marketing under its prior Class I registration, but warned that FDA disagreement could require it to stop marketing or recall devices and could result in penalties.
- The company reported 145 devices shipped to more than 100 rehabilitation centers, distributors and individual users. It announced SmartAssist and Ekso GT integration with functional electrical stimulation in June 2015; it was also assessing customer interest in industrial exoskeletons, with prototypes undergoing field testing.
- Customer concentration was notable: one customer accounted for 32% of Q2 sales; two accounted for 27% and 11% of first-half sales. Two customers represented 26% and 10% of receivables at June 30.
- Management concluded disclosure controls and procedures were not effective as of June 30, 2015, because recently implemented remediation controls had not operated long enough to be adequately tested. Management said the financial statements fairly presented the company’s financial condition and results.
- Management said ordinary-course legal matters were not expected to have a material adverse effect, and reported no material changes to the risk factors in its 2014 Form 10-K.
Important facts for investors to verify
- Progress and timing of FDA 510(k) review, and whether continued marketing remains permitted.
- Actual cash burn, runway against the stated second-quarter 2016 estimate, and terms and timing of additional financing.
- Whether device sales growth and engineering-services margins can support improvement while fleet-upgrade costs and operating investment remain elevated.
- Customer concentration, receivables collection, and potential effects of sales variability or foreign-currency movements.
- Whether control remediation is operating effectively and whether any further material weaknesses are identified.